1540 related articles for article (PubMed ID: 12506268)
1. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
4. [Reduction of prolonged QTc-interval related risks in treatment with neuropharmacological drugs. Recommendations for clinical practice].
van de Kraats GB; Slob J; Tenback DE
Tijdschr Psychiatr; 2007; 49(1):43-7. PubMed ID: 17225205
[TBL] [Abstract][Full Text] [Related]
5. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
Gury C; Canceil O; Iaria P
Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
[TBL] [Abstract][Full Text] [Related]
7. Schizophrenia and sudden cardiac death: a review.
Koponen H; Alaräisänen A; Saari K; Pelkonen O; Huikuri H; Raatikainen MJ; Savolainen M; Isohanni M
Nord J Psychiatry; 2008; 62(5):342-5. PubMed ID: 18752109
[TBL] [Abstract][Full Text] [Related]
8. The safety of atypical antipsychotics: does QTc provide all the answers?
Nielsen J
Expert Opin Drug Saf; 2011 May; 10(3):341-4. PubMed ID: 21504386
[TBL] [Abstract][Full Text] [Related]
9. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
10. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia.
Ozeki Y; Fujii K; Kurimoto N; Yamada N; Okawa M; Aoki T; Takahashi J; Ishida N; Horie M; Kunugi H
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):401-5. PubMed ID: 20079791
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
12. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
Lawrence KR; Nasraway SA
Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
[TBL] [Abstract][Full Text] [Related]
13. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of antipsychotics used in bipolar illness.
Piepho RW
J Clin Psychiatry; 2002; 63 Suppl 4():20-3. PubMed ID: 11913671
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
16. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
Kecskeméti V
Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
[TBL] [Abstract][Full Text] [Related]
17. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
18. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic agents associated with QT interval prolongation.
Olsen KM
J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
[TBL] [Abstract][Full Text] [Related]
20. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
